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Innate immunity is key to the fight against the daily onslaught from viruses that our bodies
are subjected to. Essential to this response are the interferons (IFNs) that prime our cells
to block viral pathogens. Recent evidence suggests that theType III (λ) IFNs are intimately
associated with the immune response to hepatitis C virus (HCV) infection. Genome-wide
association studies have identified polymorphisms within the IFN-λ gene locus that corre-
late with response to IFNα-based antiviral therapy and with spontaneous clearance of HCV
infection. The mechanisms for these correlations are incompletely understood. Restricted
expression of the IFN-λ receptor, and the ability of IFN-λ to induce IFN-stimulated genes
in HCV-infected cells, suggest potential roles for IFN-λ in HCV therapy even in this era of
directly acting antivirals. This review summarizes our current understanding of the IFN-λ
family and the role of λ IFNs in the natural history of HCV infection.
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HEPATITIS C VIRUS
Hepatitis C virus (HCV) is a positive sense, single-stranded RNA
virus in the family Flaviviridae. It is estimated that as many as 160
million people are chronically infected worldwide with 3–4 mil-
lion new infections every year (1, 2). With a global prevalence of
2.35%, estimated to range between 0.14% on the island of Reunion
and 14% in Egypt (1), there is a large economic cost and burden
to society.
Transmission of HCV usually occurs following contact with
infected blood through the percutaneous route, e.g., unsafe needle
sharing, but may also occur through sexual transmission, iatro-
genic, or vertical transmission routes. Following acute infection
spontaneous resolution can occur while infected individuals that
fail to clear the virus develop a chronic infection leading to liver
disease, including fibrosis, cirrhosis, and hepatocellular carcinoma.
Estimates of spontaneous clearance rates range from 14 to 45%
depending on the population studied (3). One of the major risk
factors for chronicity is HCV genotype. Currently, seven geno-
types and multiple sub-types of HCV have been identified (4).
Most patients are infected with only one genotype rather than
multiple genotypes and within an individual the virus will mutate
to form multiple genetic variants, called a quasispecies (5).
HCV CELL CULTURE
In vivo and vitro, HCV primarily infects human hepatocytes. It
has been possible to reconstitute the replication cycle of HCV in
human non-hepatic cells such as 293T cells in vitro (6), and even
in mice (7). Both of these approaches required the addition of
extra host factors; both 293T cells and mice required the HCV
entry factors claudin-1 (CLDN1) and CD81, in addition, 293T
cells required occludin (OCLN), scavenger receptor class B type
I (SR-BI), and the human micro RNA miR-122, while effective
HCV RNA replication in mice also required the knockdown of
murine innate immune mediators (7–9). Key to the replication in
non-human cells seems to be the expression of the human micro
RNA miR-122 (9). miR-122 has been shown to bind to the 5’ UTR
of HCV and to enhance translation and replication of HCV RNA
(10–14), thus, enhancing HCV propagation (15).
Experimental investigations with HCV are mainly carried out
using cell-culture models. Historically, HCV was first propagated
in permissive human hepatoma cell lines derived from Huh-7. Ini-
tially, only low-level replication was possible, but selection using
interferon alpha (IFN-α) allowed for the isolation of cell lines
that were highly permissive for replication, producing high-viral
titers, including Huh-7.5 (16, 17). Key to the progression of HCV
research was the development of HCV replicon systems (18). These
consist of a minimal HCV genome (NS3 to NS5B non-structural
genes flanked by the 5′ and 3′ UTRs) combined with a selection
marker and/or reporter gene that is incapable of producing infec-
tious virus but is capable of RNA replication in vitro. Another great
leap occurred in 2005 when a number of groups (19–21) advanced
the replicon system to show that HCV could undertake a full cycle
in cell culture to produce infectious virus. This followed the identi-
fication of an HCV isolate that was replication competent without
requiring tissue culture-adapting mutations (22).
Due to the limited host range of HCV, it has not been pos-
sible until recently to use small animal models of infection, and
serum clinical isolates of HCV replicate poorly in tissue culture.
The use of adult primary human hepatocytes (PHH) is the closest
in vitro model of HCV infection that is currently available. Unfor-
tunately, the availability of these is limited, resulting only from
organ donation or patient biopsy. Infection efficiency of PHH is
low and outcome of infection is highly variable. Even so, a number
of studies are now being published using these cells (23–26).
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FIGURE 1 | Schematic of the IFNL gene locus. The IFNL1-4 genes are
shown in their correct orientation and position in the region of chromosome
19 q13. Based on the human genome sequence, the nucleotide positions of
the first exon of each gene are indicated. The primary SNPs, rs12979860,
rs368234815, and rs8099917, affecting IFNL3 and IFNL4 are depicted with
their corresponding nucleotide position. IFNL4 is located on the reverse
strand of chromosome 19, has 5 exons and 3′/5′ untranslated regions. All
nucleotide positions are based on Ensembl genome assembly GRCh38
(December 2013), updated August 2014, database version 76 (45). Adapted
from Ref. (46).
In contrast to adult PHH, only a handful of studies have used
primary fetal human hepatocytes (FHH) (27–31). These cells are
long-lived and support sustained low levels of HCV replication.
INTERFERONS
As a positive sense single-stranded RNA virus, HCV replication
necessitates the generation of double-stranded RNA intermediates
(32). The infected cell identifies this as a major pathogen associ-
ated molecular pattern (PAMP), recognized by pattern recognition
receptors (PRRs). These immune sensing molecules can be classi-
fied into groups, i.e., the RIG-I like receptors (RLRs), the toll-like
receptors (TLRs), and the viral DNA sensors (33). Once activated
these sensing molecules trigger a number of signaling pathways,
resulting in the generation of Type I and III interferons (IFNs) and
proinflammatory cytokines.
Identified more than 50 years ago by Alick Isaacs and Jean
Lindenmann (34, 35), IFNs are the mainstay for fighting viral
infections. In human beings, there are three classes of IFNs, Types
I, II, and III, mainly classified on their binding to specific IFN
receptors. There are multiple type I IFNs, including multiple sub-
types of IFN-α, -β, -ε, -κ, and -ω, and all signal through the
IFNAR complex (36). In contrast, Type II IFN comprises only
one molecule, IFN-γ, which signals through the IFN-γR complex
(37). Receptor binding stimulates a cascade of signal transduc-
tion events, discussed in detail below, and triggers an expression
of IFN-stimulated genes (ISGs) that mediate a host of antiviral
effects [reviewed by Schoggins and Rice (38)].
There are four known Type III IFNs, namely, IFNλ1–4 (gene
names: IFNL1–IFNL4). These four genes are all located in a
small region on the long arm of chromosome 19 (39–41) and
are thought to have arisen as a result of gene duplication
(42), see Figure 1. Upon the discovery of IFNL4, the HUGO
Nomenclature Committee renamed IL29, IL28A, and IL28B to
IFNL1, -L2, and -L3 respectively (39–41). These cytokines signal
through a heterodimeric complex consisting of the ligand-binding
chain, IFN-λR1 (IL-28Rα) and the accessory chain IL-10R2
(39, 40, 43, 44).
RESTRICTED EXPRESSION OF THE IFN-λ RECEPTOR
Whereas the Type I IFN receptor IFNAR and the IL-10R2 sub-
unit of the IFN-λ receptor are present on virtually all human cell
types, the second IFN-λ receptor subunit IFN-λR1 is expressed
primarily on cells of epithelial cell origin (47) so only organs with
high-epithelial cell numbers express detectable levels of IFN-λ
(e.g., skin, intestine, and lungs). As expected, in vitro response
to IFN-λ depends on the expression of IFN-λR1. In cells that
lack the receptor, overexpression of IFN-λR1 can restore IFN-λ
responses (48).
The greater induction of ISGs following stimulation by IFN-α
compared to IFN-λmay be due in part to the number of receptors
expressed by individual cells.
Human hepatic cells express both subunits of the IFN-λ recep-
tor (IFNλ-R1 and IL10R2) (49). Addition of IFN-λ to hepatic
cell lines (such as Huh-7, HepG2), Huh-7 HCV replicon express-
ing cell lines (49) and human primary hepatocytes (50) causes
STAT1 phosphorylation and induction of ISGs, while induction
was not seen following the addition of IFN-λ to primary human
monocytes and lymphocytes (50) or mouse hepatocytes (51). As
leukocytes and peripheral blood mononuclear cells (PBMCs) from
human donors express only 6% of the level of IFNλ-R1 compared
to Huh-7, this may explain their lack of response (49).
SIGNAL TRANSDUCTION IN RESPONSE TO TYPE III IFNs
Signal transduction in response to Type III IFNs is similar to
that seen with Type I IFN [reviewed by Au-Yeung et al. (52)],
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FIGURE 2 | IFN-λ signal transduction. Type III interferon binding to the
IFN-λ receptor and type I interferon binding to the IFNAR both activate the
JAK1/STAT pathway to form the ISGF3 complex. ISGF3 relocates from the
cytosol to the nucleus whereupon binding to ISREs induces the expression
of ISGs such as myxovirus (influenza virus) resistance 1 (MX1), melanoma
differentiation-associated protein 5 (MDA5), and 2′-5′ oligoadenylate
synthetase (OAS), see text for details.
and is summarized in Figure 2. When Type III interferon binds
to IFN-λR1, a conformational change allows the binding of IL-
10R2 activating the receptor-associated tyrosine kinases Janus
kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) to cross-tyrosine-
phosphorylate the IFN-λR1/IL-10R2 receptor complex allowing
the recruitment of signal transducer and activator of transcrip-
tion (STAT) 2 via its Src Homology 2 (SH2) domain. Further
JAK tyrosine-phosphorylation of STAT2 allows the binding of the
SH2 domain from cytoplasmic STAT1, resulting in the forma-
tion of a STAT1/STAT2 heterodimer. STAT2 is normally bound
to IFN regulatory factor 9 (IRF9) in the cytosol, where it shut-
tles between the nucleus and cytosol. The addition of IRF9 to
the complex forms a heterotrimeric transcription complex called
IFN-stimulated gene factor 3 (ISGF3). IFN-λ may also activate
STATs 3–5, although the significance of this activation has not been
studied (53). Once assembled, ISGF3 relocates from the cytosol
to the nucleus where it binds to interferon stimulated response
elements (ISREs) upstream of ISGs [reviewed by Reich (54)],
encoding proteins such as myxovirus (influenza virus) resistance
1 (MX1), melanoma differentiation-associated protein 5 (MDA5),
and 2′-5′ oligoadenylate synthetase (OAS). The IFN-α and IFN-λ
induction of these ISGs is reduced in STAT1 deficient hepato-
cytes, consistent with the requirement of STAT1 for formation of
the ISGF3 complex (50). In HepG2 cells, induction of IFN-α and
IFN-β is not seen when cells are stimulated with IFN-α or IFN-
λ but these same cytokines do induce IFN-λ (55). Therefore, in
contrast to the Type I IFNs, Type III IFNs are themselves ISGs.
Other pathways may also be activated by IFN-λ, including the
AKT signaling pathway (56). In common with Type I IFN, stim-
ulation of cells with IFN-λ leads to phosphorylation, and hence
activation of the mitogen-activated protein kinase (MAPK) c-Jun
N-terminal kinase (JNK), although evidence for the activation of
MAPK p38 or extracellular-signal-regulated kinases (ERK) 1/2 is
conflicting (48, 57) and may depend on cell type.
As Type I and Type III IFN share similar signal transduction
mechanisms, the repertoire of ISGs induced upon cytokine stim-
ulation is predicted to be similar. Most microarray analysis and
RT-PCR studies have shown IFN-λ induces essentially the same
genes as IFN-α in HepG2 cells, Huh-7.5 cells containing a full-
length HCV replicon (FL-neo), Huh-7.5 cells, and primary mouse
and human hepatocytes (50, 58–60). Of note, a study by Bauhofer
et al. (61) suggests that the differentiation state of these cells
may alter the repertoire of gene induction. They showed that a
wider range of ISGs were induced in IFN-α or -λ treated dimethyl
sulfoxide differentiated Huh-7.5 (Huh-7.5dif) and PHH cells, as
compared to IFN-α or -λ treated wild-type Huh-7.5 cells (61).
Although most of the above-mentioned studies show similar
gene expression repertoires after stimulation with IFN-α or IFN-λ,
the kinetics, and magnitude of induction are different. In a study
comparing global transcriptional profiles over time, Bolen et al.
identified a difference in the scale of ISG induction between dif-
ferent cytokines in both Huh-7 cells and primary hepatocytes (62)
with IFN-β> IFN-α> IFN-λ3> IFN-λ1> IFN-λ2. In this exper-
iment, the same set of genes were induced with all the cytokines
but whereas IFN-α stimulated gene expression wanes after approx-
imately 6 h, IFN-β and IFN-λ1–3 stimulated gene expression con-
tinues at a high level for >24 h. The greater specific activity (ISG
induction) of IFN-λ3 over other Type III IFNs as shown by Bolen
et al. has also been replicated by Dellgren et al. (63) who showed
that IFN-λ3 is 16-fold more active than IFN-λ2 and 2-fold more
active than IFN-λ1. A recent comparison between IFN-λ3 and
IFN-λ4 has shown comparable specific activity (44). One possi-
ble explanation for the differences in the scale of ISG induction
between IFN-α and IFN-λ may be due to transcription factor
binding differences. Chromatin immunoprecipitation assays show
that less efficient remodeling at promoter sites occurs following
stimulation by IFN-λ compared to IFN-α (48). Blocking signaling
through the Type I receptor, IFNAR, does not abrogate the activity
of IFN-λ (50). IFN-λ signaling was shown to be enhanced by HCV
infection of Huh-7.5 cells, an observation, which has been attrib-
uted to up-regulation of IFN-λR1 and prolongation of JAK-STAT
signaling within those cells (60).
EXPRESSION OF IFN-λ
Up-regulation of IFN-λ is seen following infection of different cells
by diverse viruses such as encephalomyocarditis virus (EMCV),
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murine cytomegalovirus, reovirus, Sendai virus, dengue virus, and
measles virus (39, 40, 64, 65), probably following RLR signaling
from the peroxisome (65). Although expression of both IFN Type
I and III are triggered in similar ways, differential expression can
clearly be seen in organs such as the brain and central nervous sys-
tem where IFN Type III expression is minimal compared to Type
I IFN expression, following viral infection (47). Dendritic cells
(DCs) can express IFN-λ on stimulation with double-stranded
RNA and TLR3 ligand (66).
Within the liver there is an expression of both IFN-α and -λ
but identification of the cell types that express IFN-λ within the
infected liver is difficult to determine. It is known that freshly
isolated primary FHH express IFN-λ when infected with HCV
(30, 31). Until recently, it was not possible to distinguish a par-
ticular cytokine expressing cell within a population. However,
in an elegant set of experiments carried out by Sheahan et al.
(31), the expression profiles of individual fetal hepatocytes were
determined following laser capture micro-dissection. Type III
interferon induction was observed only in HCV-infected FHH
cells and not by surrounding bystander cells. Furthermore IFNL1
expression was found to be dependant on HCV replication as
blocking viral replication using 2′CMA (a viral replicase inhibitor)
abrogated IFN-λ1 protein secretion (31).
Although there are no studies addressing the issue of IFN-λ
secretion by DCs within the HCV-infected liver, it is known that
DCs can secrete IFN-λ following in vitro stimulation (55, 66–
68). As it is unlikely that DCs support significant HCV replication,
exposure to the viral PAMP is thought to occur via interaction with
infected hepatocytes, endocytosis of HCV virions, or exposure to
viral RNA following immune cell induced death of HCV-infected
cells.
There is conflicting evidence for the up-regulation of IFN-
λ in HCV chronically infected liver. Some studies have shown
upregulated serum levels of IFN-λ in chronic HCV patients when
compared to serum levels of patients with either non-viral diseased
livers or control non-diseased livers (49, 69), while others have
shown lower IFN-λ serum levels in chronic HCV livers compared
to non-diseased livers (70). During analysis of IFN-λ transcripts
in liver biopsies, Mihm et al. showed no difference between HCV
diseased liver and non-viral diseased liver although an increase
in IFN-λ transcripts can be seen when HCV-infected livers were
compared to healthy livers (71, 72). In vitro studies show that
HCV infection causes IFN-λ transcription in PHH, FHH, and the
human hepatocyte cell line PH5CH8 (30, 72).
SEQUENCE HOMOLOGY OF IFN-λ1–4
IFN-λ1–3 were discovered by two independent research groups
following sequence analysis of the human genome (39, 40), while
IFNλ-4 was discovered when genome-wide association study
(GWAS) data were compared to RNA-seq analysis of PHHs treated
with polyinosinic:polycytidylic acid (polyI:C), a synthetic mimic
of double-stranded RNA (41).
IFN-λ1–4 are similar in amino-acid sequence (41–97% amino-
acid conservation), especially within the first and last alpha helices,
which are the primary regions of contact between Type III IFNs
and their receptor, IFN-λR1 (see Figure 3; Table 1). Outside of
these regions IFN-λ4 is less similar to IFN-λ1–3 having only 30%
amino-acid identity. One notable region where amino-acid con-
servation is poor is α-helix 3, a region predicted to interact with
the IFN-λ receptor subunit IL10R2 (44, 73). IFN-λ2 and IFN-λ3
are the most similar, with approximately 96% amino-acid identity
(seven amino-acid differences) within their coding sequences and
virtually identical within their non-coding upstream and down-
stream flanking sequences (41). Despite this similarity between
IFN-λ2 and -3, it is remarkable that there is a 16-fold difference
in specific activity (63). The reasons for this are as yet unclear, but
it is interesting to note that these differences are also located in
the region that is predicted to interact with the IFN-λ receptor
subunit IL10R2.
Currently, two protein structures have been determined for
IFN-λ; IFNλ3 (3HHC) (76) and IFNλ1 in complex with its recep-
tor IFN-λR1 (3OG6) (77). These show that the IFN-λs exist as
monomers and bind to the IFN-λR1 receptor as a 1:1 complex.
The structure of IFN-λ3 shows that it is most closely related to
IL-22, a member of the IL-10 family (76).
The transcription factors that regulate expression of the IFN-
λ genes are currently unclear. Conflicting studies have shown
requirements for IRF7 alone (IFN-α like), IRF7 plus IRF3 (IFN-β
like), or IRF7, IRF3, and NF-κB (72, 78, 79). This uncertainty may
be due to the wide range of cell lines used, induction protocols, and
the species of IFN-λ used. Knockdown of the p65 subunit of NF-
κB decreased IFNL1 transcription in response to HCV and PolyI:C,
whereas NF-κB was dispensable for the expression of IFNL2 and
IFNL3 (72). Lee et al. suggested that this differential requirement
for NF-κB could be the basis of the differential expression of the
IFN-λ gene family. Recently, another transcription factor of IFNLs,
Med23, was discovered to interact directly with IRF7, leading to
the up-regulation of IFN-λ (80).
IFN-λ INHIBITS HCV
Studies of HepG2 cells expressing miR-122 and CD81, primary
human hepatocytes, and chimpanzee and human in vivo studies
have all shown that HCV induces primarily an IFN-λ response
rather than IFN-α or -β (30, 31, 72, 81–83). IFN-λ can then
act in an autocrine fashion, stimulating the expression of ISGs
(30, 82). Exogenous addition of IFN-λ to hepatocytes inhibits
replication of both HCV replicons (49, 58, 59, 84, 85) and cell
culture-derived HCV (30, 31, 60, 70, 72, 82). In HCV replicon cell
lines, recombinant IFNL1 had a greater effect on HCV replication
than IFNL2 and IFNL3 (85). IFNL1 also induces STAT1 phospho-
rylation more readily than IFNL2/3 (49, 85), while no differences
are seen between IFNL3 and IFNL4 (44). This is not the case when
comparing IFN-λ activity against EMCV in HepG2 cells. Dellgren
et al. (63) showed that against EMCV, IFNL3 was the most active
of IFNL1–3. Concomitant with a reduction in HCV replication,
IFN-λ also suppresses the microRNA miR-122 (72). The addition
of both IFN-λ and the miR-122 inhibitor (miRIDIAN) increased
the suppression of HCV replication (72).
IFN-λ AS A THERAPY
Until recently, the standard therapy for chronic HCV was the use
of pegylated interferon-α (Peg-IFN) in combination with ribavirin
(RBV). Unfortunately, these regimens were poorly tolerated and
often ineffective, with treatment efficacy varying among different
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FIGURE 3 | Protein sequence analysis. Clustal multiple sequence alignment
by MUSCLE (3.8) for IFN-λs, IFNL1–4. Protein IDs are Q8IU54, Q8IZJ0,
Q8IZI9, and K9M1U5-1, respectively. Identical amino-acids are shaded in
black, conserved amino-acids are represented by a colon (:) and
semi-conserved amino-acids by a period (.). Alpha helices are indicated and
are based on the crystal structure of IFNL3 (3HHC chain A) (73–75).
Table 1 | Amino-acid conservation table.
IFNL1 IFNL2 IFNL3 IFNL4
IFNL1 100 69.5 71.9 30.7
IFNL2 76.5 100 96.4 26.8
IFNL3 78.1 97.4 100 29.6
IFNL4 44.1 41.3 44.7 100
Clustal pairwise alignments by MUSCLE (3.8) were carried out for IFN-λs, IFNL1–
4. Protein IDs are Q8IU54, Q8IZJ0, Q8IZI9, and K9M1U5-1, respectively. Percent
amino-acid conservation (%) was calculated from each pairwise alignment. Iden-
tical conservation is shown in normal type and conserved conservation is shown
in italic type (75).
HCV genotypes and among patients of different ethnic back-
grounds or different comorbid conditions (86). Treatment with
Peg-IFN and RBV results in sustained virologic response (SVR)
in approximately 40–50% of genotype 1-infected people and 80%
in those infected with genotypes 2 or 3 (2). HCV treatment is
evolving rapidly, and current regimens for genotype 1-infected
patients include either telaprevir or boceprevir, first-generation
direct-acting antivirals (DAAs). These protease inhibitors (PIs)
need to be administered in combination with Peg-IFN and RBV
in order to reduce the likelihood of viral drug resistance. The addi-
tion of PIs leads to an increase in the likelihood of SVR to between
63 and 92% (2).
Following the discovery that the receptor for IFN-λ is cell-
type restricted compared to the IFNAR receptor, it was thought
that administration of IFN-λ would have fewer off-target effects
and therefore patients would suffer fewer adverse side effects. As
reports from in vitro studies suggested that HCV was sensitive to
IFN-λ, there was hope that IFN-λs could be used therapeutically
to combat HCV. Those hopes have largely been realized following
Phase 1 trials looking at the use of pegylated IFN-λ in the treat-
ment of genotype 1 chronic HCV infection (87, 88). The Muir et al.
study compared treatment regimens consisting of Peg-IFN-λ or
Peg-IFN-λ+RBV in IFN-α treatment-relapsed patients (patients
who had relapsed following at least 12 weeks treatment with Peg-
IFN-α+RBV) and Peg-IFN-λ+RBV in treatment-naïve patients.
Although SVR was not evaluated in this study (being only 4 weeks
long), the majority of patients displayed antiviral activity with a
>2-log10 decrease in HCV RNA; in the case of treatment-naïve
patients, 2 out of 7 achieved transient undetectable HCV RNA.
Encouragingly, the administration of Peg-IFN-λwas well tolerated
in both of the phase 1 trials with few adverse events. A possi-
ble reason for this effect with Peg-IFN-λ is that unlike IFN-α,
which can produce a long-lasting refractoriness in JAK-STAT sig-
naling (89), the use of Peg-IFN-λ induces signaling even following
multiple or prolonged stimulations (90) and may also be able to
overcome pre-existing refractoriness due to previous treatment
with IFN-α.
Although the treatment for chronic HCV is heading toward
IFN-free regimens with the development of DAAs that target either
the HCV RNA polymerase (e.g., sofosbuvir) or non-structural
protein NS5A (e.g., daclatasvir or ledipasvir), these treatments are
costly and it is not yet known whether these treatments will be
applicable to all genotypes. It may be some time until the use of
IFN is discontinued, be it α or λ.
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Table 2 | SNPs at the IFNL locus.
Variant Genotype Protective Non-protective Gene Position in genome Reference
rs8103142 T/C; K70R T K70 C R70 IFNL3 39244466 (98)
rs12979860 C/T C T IFNL4 39248147 (91, 92)
rs368234815 TT/∆G TT ∆G IFNL4 39248514–39248515 (41, 99)
rs8099917 T/G T G 5′ of IFNL4 39252525 (91, 94, 95)
Table showing the common SNPs that have been associated with HCV clearance following either treatment with Peg-IFN+RBV or spontaneous clearance.
GENOME-WIDE ASSOCIATION STUDIES
A number of independent groups have identified single nucleotide
polymorphisms (SNPs) located near the IFN-λ3 locus that cor-
relate with HCV treatment response and spontaneous clearance
of HCV infection. These are summarized in Table 2. The poly-
morphisms include rs12979860 (C/T) (91–93) and rs8099917
(T/G) (94–97). The rs12979860 SNP is located approximately 3 kb
upstream of the IFNL3 gene, within an intron of IFNL4, while the
rs8099917 SNP is located within an intergenic region between the
IFNL2 and IFNL3 genes.
These SNPs have been associated with SVR following treat-
ment of chronic HCV with Peg-IFN and RBV (91, 94, 95, 97) and
also with spontaneous clearance of HCV infection (92, 96, 100)
[reviewed by O’Brien et al. (46)]. It has been shown that individ-
uals with the non-beneficial rs12979860-T allele (C/T or T/T) do
not respond as well to standard therapy as those individuals with
two copies of the beneficial rs12979860-C (C/C) allele. The preva-
lence of the non-beneficial rs12979860-T allele is higher in people
of African ancestry than in those of European or Asian ancestry.
In a similar manner, individuals with two copies of the beneficial
rs8099917-T (T/T) allele respond better than those individuals
with one or no copies of the non-beneficial T allele (T/G or G/G)
(94). As the rs12979860 and rs8099917 SNPs are in linkage dise-
quilibrium (LD) with each other, favorable rs8099917 alleles are
also more prevalent in Europeans/Asians compared to Africans.
Although Melis et al. did not look at patient data they have devel-
oped a method to analyze both rs12979860 and rs8099917 (101),
which may provide greater predictability in treatment outcomes.
Recently, two groups identified a possible causal SNP upstream
of the IFNL3 gene, rs368234815 (TT or ∆G) (originally desig-
nated ss469415590) (41, 46, 99). This SNP results in a frameshift
mutation leading to the polyI:C mediated transient expression
of a new IFN-λ, now termed IFNL4 (41). The IFNL4 protein is
made in IFNL4-∆G carriers but not IFNL4-TT homozygotes. In
addition, due to its location within a CpG island upstream of
IFNL3, the TT/∆G polymorphism is responsible for the methy-
lation of a cytosine residue, which may influence gene expression
(99). IFNL4-∆G is strongly associated with impaired spontaneous
clearance. In African-Americans, the IFNL4-∆G SNP has been
shown to be a better marker for predicting response following
Peg-IFN and RBV than rs12979860 (41, 102). This is in contrast to
European- and Asian-Americans where the two SNPs are equally
informative (41). This discrepancy is due to the differences in the
degree of LD between these SNPs within these populations (99).
Recently, another possible causal SNP was detected, rs8103142
(98). This polymorphism is present within the second exon of
IFNL3 and changes the amino-acid lysine at position 70 to arginine
(K70R). Interestingly, this amino-acid is one of only seven that
are different between IFNL2 and IFNL3 (73). Given that IFNL3
has a 16-fold greater specific activity than IFNL2, a number of
groups have studied the functional consequences of this substitu-
tion in vitro (85, 103, 104); however, they were unable to show any
difference in anti-HCV replicon activity or in the stimulation of
its activity.
The molecular mechanism for the association between treat-
ment outcome and IFN-λ SNPs is not known. The positions of
these SNPs, in the vicinity of IFNL3 and IFNL4, suggest that they
may be involved in transcriptional regulation although the evi-
dence for this is conflicting. Ge et al. (91) were unable to detect
a relationship between IFNL3 mRNA levels and rs12979860 poly-
morphism in PBMCs from non-HCV-infected patients; Urban
et al. showed that there was no significant difference in IFNL2/3
mRNA expression in HCV-infected liver tissue (103). In contrast,
the presence of the non-beneficial G allele for SNP rs8099917
was associated with lower levels of IFN-λ expression in PBMC
taken from HCV-infected patients (95) and also whole blood from
healthy individuals (94), but there was no significant difference
in IFNL3 mRNA expression between rs8099917 genotypes in a
study carried out by Honda et al. (105). Conversely, carriers of the
protective rs12979860 C allele were shown to have higher serum
protein levels of IFN-λ (70), although this may be due to LD with
the IFNL4 associated SNP, rs368234815. In a publication by Bibert
et al., PBMCs from individuals carrying different allelic combina-
tions of rs12979860 and rs368234815 were stimulated with polyI:C
and the expression of IFNL3 mRNA was measured. Their study
showed lower expression of IFNL3 mRNA in PBMCs from indi-
viduals carrying one or two copies of the mutant∆G allele but not
by rs12979860 (99). This study also showed that the plasma level
of the ISG, IFN-γ-inducible protein 10 (IP-10), was reduced in
individuals carrying the rs368234815 non-beneficial allele but not
in those carrying the rs12979860 non-beneficial allele. Another
mechanism may be the alteration of IFNL3 transcript stability via
the action of HCV induced miRNA targeting of the polymorphic
region of the IFNL3 3′ UTR (106).
As previously mentioned, miR-122 may play an important
role in HCV replication (10). No correlation between expression
of miR-122 and SNP rs12979860 genotype was seen in human
liver biopsies by Urban et al. (103) although a correlation was
seen between SVR and miR-122 expression with greater expres-
sion of miR-122 in responders compared to non-responders (NR)
(103, 107). In contrast, Estrabaud et al. showed that there was
a significant increase of miR-122 at baseline in rs12979860 CC
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genotype patients regardless of their response status (108). The
authors argue that the larger numbers of patients in their study
may explain this discrepancy (108). As miR-122 stimulates HCV
replication in vitro, and antagonism of miR-122 by the oligonu-
cleotide SPC3649 results in a decrease in serum HCV RNA in vivo
(109), the finding that a beneficial allele may increase miR-122 is
surprising. In the case of rs12979860, genotype C/C patients have a
lower baseline ISG expression (103, 105, 110), and hence a stronger
ISG activation upon infection. This innate activation may swamp
any effect on HCV replication brought about by an increase in
miR-122 (108).
In the case of IFNL4, the frameshift produced by the unfavor-
able, non-protective ∆G allele causes the production of IFN-λ4
protein. This protein was postulated to have a weak signal peptide
(SP) and subsequent poor secretion (41) but subsequent experi-
ments have shown that the SP functions correctly and that poor
secretion is due to the lack of N-linked glycosylation (44). IFN-λ4
is active without glycosylation as Escherichia coli expressed pro-
tein is able to induce ISGs in HepG2 cells to a similar level as
IFN-λ3, and addition of recombinant IFN-λ4 to Huh-7-Lunet
and HepG2 cells inhibited HCV replicon replication (44). The
presence of an IFN-λ4 protein that is able to induce ISG expres-
sion, is active against HCV, yet is associated with poorer HCV
clearance rates is counter-intuitive. Various theories have been
put forward for this effect including intracellular accumulation
of non-glycosylated IFN-λ4 could be cytotoxic and result in cell
death, or that IFN-λ4 could impede signaling by other IFN-
λs by blocking the IFN-λ receptor and causing exhaustion of
the IFN response pathways (46). IFNL4 transcripts were exclu-
sively detected in chronic HCV liver biopsies and not in control
uninfected, HBV infected, and inflammatory liver diseased liver
biopsies (111), suggesting that the IFNL4 gene is specifically acti-
vated in HCV infection. In addition, Amanzada et al. were able
to show a positive correlation between HCV viral loads and the
amount of IFNL4 transcripts. As expected, IFNL4 transcripts were
detected in all IFNL4 SNP rs368234815 genotypes but IFN-λ4
protein can only be produced in those patients with the ∆G
genotype.
It needs to be borne in mind that although GWAS studies have
allowed us to narrow down the area in which a causal variant may
reside, neither the identified SNPs nor the expression of the novel
IFNL4 gene may be the true causal variant, and these associations
may be due to some other as yet unidentified mechanism.
The IFN-λ gene region seems to have undergone genetic selec-
tion pressure, especially in the case of IFN-λ4. The negative selec-
tion of the ∆G allele and its replacement with the TT variant
in non-African populations suggests that infection with another
infectious agent may have driven this change. This geographi-
cal selective force probably occurred after the colonization of the
New World (92). Candidates such as hepatitis B and HIV have
been discounted as they do not show any association with the
known IFN-λ SNPs (112–114). Also, any such disease would need
to predate the movement of modern human beings out of Africa
and therefore pathogens such as HIV are unlikely candidates. It
remains to be seen if this polymorphism affects the outcome of
other infections.
IFN-λ AND THE ADAPTIVE IMMUNE RESPONSE
As well as its role in innate immunity, IFN-λ may have an
immunomodulatory function (115). There is currently sparse lit-
erature describing the action of IFN-λ and its effect on adaptive
immunity directed toward HCV, perhaps because leukocytes in
general do not express the IFN-λR1 receptor (116). Though some
authors have demonstrated both IFN-λR1 mRNA and cell-surface
expression in T-cells, others have not been able to replicate these
findings (117). It has been reported that DCs can acquire IFN-λ
responsiveness following up-regulation of IFN-λR1 during their
maturation from monocytes (115). If this is the case, then even
though IFN-λR1 may be absent from T-cells their function may
be altered by the interaction with IFN-λ stimulated DCs.
CONCLUSION
Recent advances in the treatment of HCV with newly developed
DAAs will revolutionize the field of HCV research but the cost of
these treatments and the side effects they may engender mean that
it is too soon to abandon HCV basic research. Many questions still
remain to be answered, especially in HCV innate immunity and
the role of IFN-λ. The identification of genetic variation at the
IFNL gene locus has allowed us to begin to understand the basis
of HCV resolution, but further research is required to appreci-
ate how the IFN-λs are involved in the progression to the chronic
state following acute infection. Future research should concentrate
on understanding IFN-λ gene regulation and the relevance of its
differential expression.
As therapy moves toward IFN-free DAA-based regimens, will
the patient genotype have an effect on SVR, and if so will this
SVR be affected by the same SNPs seen with IFN-α therapy or
will this new therapy throw up its own set of SNPs? The develop-
ment of a more relevant culture system would be advantageous
for our improved understanding of HCV pathogenesis and treat-
ment. Although the techniques of micro-patterning and 3D cell
culture are advancing, these models are not yet “user friendly.” In
the absence of these, greater use of physiologically relevant cells
such as primary hepatocytes will allow us to tease apart the intri-
cate pathways and interactions that need to be discovered if we
are to fully appreciate the complexities of the host:HCV interac-
tion. Researchers should not be afraid of the inherent donor liver
variation; as the maxim says variety is the spice of life.
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